OpportunityAnalyzer: Clostridium difficile Infections – Opportunity Analysis and Forecasts to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD. CDIs begin with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. Observed most frequently in healthcare settings, CDIs often occur when normal intestinal flora are disrupted by antibiotic administration, which can give C. difficile a competitive growth advantage if patients are exposed to the pathogen. Since 2000, CDIs have become more frequent, more severe, more difficult to treat using existing therapies, and more likely to recur than previously described. These realities, along with increasing threat of antibiotic resistance, underscore the importance of developing CDI-specific therapies and bringing them to market.
Scope
Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline CDI market revenue from 2016–2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting CDI therapeutics and prophylactics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global CDI therapeutics and prophylactics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI therapeutics and prophylactics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Shire
OpenBiome
Akthelia Pharmaceuticals
MGB Biopharma
Merck & Co.
Actelion
Summit Therapeutics
Otsuka Pharmaceuticals
Seres Therapeutics
Rebiotix
Sanofi Pasteur
Pfizer
Valneva
Synthetic Biologics
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.